ULTRAGENYX PHARMAC revenue breakdown overview

ULTRAGENYX PHARMAC revenue for the last year amounted to 508.80 M CHF, the most of which — 249.59 M CHF — came from its highest performing source at the moment, Crysvita Royalty, the year earlier bringing 153.78 M CHF. The greatest contribution to the revenue figure was made by North America — last year it brought ULTRAGENYX PHARMAC 309.21 M CHF, and the year before that — 258.60 M CHF.